Pre-made Varisacumab benchmark antibody ( Whole mAb, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Varisacumab (GNR 011), a biosimilar of bevacizumab [see Adis Insight Drug profile 800008086] is under development with International Biotech Center Generium (IBC Generium), for the treatment of various types of cancer, including colorectal, non-small cell lung, glioblastoma and breast cancer, and ophthalmic conditions.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-613-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody
INN Name	Varisacumab
Target	VEGFA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II/III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS
Conditions Approved	na
Conditions Active	Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer
Conditions Discontinued	na
Development Tech	na